Comparative analysis between avatrombopag and thrombopoietin

Avatrombopag acts as a small molecule TPO receptor agonist, which mimics endogenous TPO to stimulate the growth and development of megakaryocytes and megakaryocyte progenitor cells in the bone marrow, thereby increasing platelet production. Its TPO receptor binding site is different from endogenous TPO and binds to the transmembrane region of TPO receptor.

Thrombopoietin (TPO) is one of the formed components in mammalian blood. It is produced by megakaryocytes in the bone marrow hematopoietic tissue and regulates the production of platelets. TPO is a physiological regulator of platelet production, which can promote the proliferation and differentiation of megakaryocytes, thereby increasing the number of platelets.

Avatrombopag is FDA approved for the treatment of thrombocytopenia associated with chronic liver disease (CLD) and immune thrombocytopenia (ITP) in adults undergoing elective diagnostic procedures or surgery. Studies have shown that avatrombopag can significantly increase patients' platelet count, with long-lasting efficacy and good safety profile.

AlthoughTPO itself is not directly used in therapy, it is the basis for the development of platelet-generating drugs. By simulating the effects of TPO, platelet production can be stimulated to treat thrombocytopenia.

In vitro experiments show that there is no competitive relationship between avatrombopag and TPO in promoting platelet production, but they have additive effects. Avatrombopag is well tolerated. Common side effects include fever, fatigue, headache, etc., and most of them can be tolerated. Additionally, liver function and platelet counts need to be monitored to ensure drug safety.

As a physiological regulator, TPO itself does not have significant side effects. However, through exogenous supplementationTPO orTPOWhen agonists are used to stimulate platelet production, they may cause some adverse reactions, such as thrombosis, so they need to be used with caution.